{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:46:54Z","timestamp":1790948814696,"version":"4.1.0"},"reference-count":119,"publisher":"Wiley","issue":"10","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd015045","type":"journal-article","created":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T18:55:55Z","timestamp":1634756155000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Colchicine for the treatment of COVID-19"],"prefix":"10.1002","volume":"2021","author":[{"given":"Agata","family":"Mikolajewska","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Respiratory Medicine; Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin; Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Lena","family":"Fischer","sequence":"additional","affiliation":[{"name":"Department of Anaesthesia and Intensive care; Universit\u00e4tsklinikum Leipzig; 04103 Leipzig Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Piechotta","sequence":"additional","affiliation":[{"name":"Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anika","family":"Mueller","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Intensive Care Medicine, Campus Charit\u00e9 Mitte and Campus Virchow-Klinikum; Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, and Berlin Institute of Health; Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Inti","family":"Metzendorf","sequence":"additional","affiliation":[{"name":"Cochrane Metabolic and Endocrine Disorders Group; Institute of General Practice, Medical Faculty of the Heinrich-Heine-University D\u00fcsseldorf; D\u00fcsseldorf Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Becker","sequence":"additional","affiliation":[{"name":"Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne; University of Cologne; Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Dorando","sequence":"additional","affiliation":[{"name":"Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael L","family":"Pacheco","sequence":"additional","affiliation":[{"name":"Center of Health Technology Assessment; Hospital S\u00edrio-Liban\u00eas; S\u00e3o Paulo Brazil"},{"name":"N\u00facleo de Ensino e Pesquisa em Sa\u00fade Baseada em Evid\u00eancias e Avalia\u00e7\u00e3o Tecnol\u00f3gica em Sa\u00fade (NEP-Sbeats); Universidade Federal de S\u00e3o Paulo; S\u00e3o Paulo Brazil"},{"name":"Cochrane Affiliate Rio de Janeiro; Cochrane; Petr\u00f3polis Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Luiza C","family":"Martimbianco","sequence":"additional","affiliation":[{"name":"Center of Health Technology Assessment; Hospital S\u00edrio-Liban\u00eas; S\u00e3o Paulo Brazil"},{"name":"Cochrane Affiliate Rio de Janeiro; Cochrane; Petr\u00f3polis Brazil"},{"name":"Postgraduate Program in Health and Environment; Universidade Metropolitana de Santos (UNIMES); Santos Brazil"},{"name":"N\u00facleo de Ensino e Pesquisa em Sa\u00fade Baseada em Evid\u00eancias e Avalia\u00e7\u00e3o de Tecnologias em Sa\u00fade (NEP-Sbeats); Universidade Federal de S\u00e3o Paulo; S\u00e3o Paulo Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Riera","sequence":"additional","affiliation":[{"name":"Cochrane Affiliate Rio de Janeiro; Cochrane; Petr\u00f3polis Brazil"},{"name":"N\u00facleo de Ensino e Pesquisa em Sa\u00fade Baseada em Evid\u00eancias e Avalia\u00e7\u00e3o de Tecnologias em Sa\u00fade (NEP-Sbeats); Universidade Federal de S\u00e3o Paulo; S\u00e3o Paulo Brazil"},{"name":"Centre of Health Technology Assessment; Hospital S\u00edrio-Liban\u00eas; S\u00e3o Paulo Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Skoetz","sequence":"additional","affiliation":[{"name":"Cochrane Cancer, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Stegemann","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Respiratory Medicine; Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin; Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,10,18]]},"reference":[{"issue":"6","key":"10.1002\/14651858.CD015045-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1001\/jamanetworkopen.2020.13136","article-title":"Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019: the GRECCO-19 randomized clinical trial","volume":"3","author":"Deftereos","year":"2020","journal-title":"JAMA Network Open"},{"issue":"1","key":"10.1002\/14651858.CD015045-BIB0002|cit2","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.hjc.2020.03.002","article-title":"The Greek study in the effects of colchicine in COvid-19 complications prevention (GRECCO-19 study): rationale and study design","volume":"61","author":"Deftereos","year":"2020","journal-title":"Hellenic Journal of Cardiology"},{"key":"10.1002\/14651858.CD015045-BIB0003|cit3","unstructured":"Colchicine in patients admitted to hospital with 3 COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial medRxiv www.medrxiv.org\/content\/10.1101\/2021.05.18.21257267v1"},{"issue":"1","key":"10.1002\/14651858.CD015045-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"e001455","DOI":"10.1136\/rmdopen-2020-001455","article-title":"Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial","volume":"7","author":"Lopes","year":"2021","journal-title":"RMD open"},{"issue":"8","key":"10.1002\/14651858.CD015045-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S2213-2600(21)00222-8","article-title":"Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial","volume":"9","author":"Tardif","year":"2021","journal-title":"Lancet Respiratory Medicine"},{"key":"10.1002\/14651858.CD015045-BIB0006|cit6","doi-asserted-by":"crossref","unstructured":"Tardif JC Bouabdallaoui N L'Allier PL Gaudet D Shah B Pillinger MH Efficacy of colchicine in non-hospitalized patients with COVID-19 www.medrxiv.org 2021 doi.org\/10.1101\/2021.01.26.21250494","DOI":"10.1101\/2021.01.26.21250494"},{"key":"10.1002\/14651858.CD015045-BIB0007|cit7","unstructured":"Colchichine use for preventing COVID infection in haemodialysis patients ctri.nic.in\/Clinicaltrials\/pmaindet2.php?trialid=45658"},{"key":"10.1002\/14651858.CD015045-BIB0008|cit8","unstructured":"Open label randomized trial of colchicine, aspirin and montelukast in Covid-19 www.who.int\/trialsearch\/Trial2.aspx?TrialID=CTRI\/2020\/09\/028088"},{"key":"10.1002\/14651858.CD015045-BIB0009|cit9","unstructured":"Evaluation of therapeutic effect of MAB98 including thymolic fraction of trachyspermum ammi, thymoquinone fraction of nigella sativa and colchicine of colchicum autumnale in Covid 19 patients www.irct.ir\/trial\/49249"},{"issue":"2","key":"10.1002\/14651858.CD015045-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"15","DOI":"10.18087\/cardio.2021.2.n1560","article-title":"Proactive anti-inflammatory therapy with colchicine in the treatment of advanced stages of new coronavirus infection. The first results of the COLORIT study","volume":"61","author":"Mareev","year":"2021","journal-title":"Kardiologiia"},{"key":"10.1002\/14651858.CD015045-BIB0011|cit11","unstructured":"Effectiveness and safety of medical treatment for SARS-CoV-2 (COVID-19) in Colombia clinicaltrials.gov\/ct2\/show\/NCT04359095"},{"key":"10.1002\/14651858.CD015045-BIB0012|cit12","unstructured":"Colchicine plus phenolic monoterpenes to treat COVID-19 clinicaltrials.gov\/ct2\/show\/NCT04392141"},{"key":"10.1002\/14651858.CD015045-BIB0013|cit13","unstructured":"Treatment for moderate\/severe COVID-19 in a fragile and vulnerable population, admitted to a geriatric hospital unit or in a transicional care center clinicaltrials.gov\/show\/NCT04492358"},{"key":"10.1002\/14651858.CD015045-BIB0014|cit14","unstructured":"Study to investigate the benefits of colchicine in patients with COVID-19 clinicaltrials.gov\/show\/NCT04603690"},{"key":"10.1002\/14651858.CD015045-BIB0015|cit15","unstructured":"Efficacy and safety of colchicine on clinical improvement in patients with COVID-19: a randomized, double blind clinical trial www.irct.ir\/trial\/54385"},{"key":"10.1002\/14651858.CD015045-BIB0016|cit16","unstructured":"Investigation of the efficacy and safety of colchicine In combination with standard treatment on covid-19 patients: a clinical trial www.irct.ir\/trial\/46867"},{"key":"10.1002\/14651858.CD015045-BIB0017|cit17","unstructured":"Evaluation of colchicine tablet efficacy as an adjuvant treatment for patients with mild to moderate COVID-19 in Qaem Hospital, Mashhad: a triple-blind randomized placebo controlled clinical trial en.irct.ir\/trial\/47468"},{"key":"10.1002\/14651858.CD015045-BIB0018|cit18","unstructured":"Colchicine efficacy in COVID-19 pneumonia clinicaltrials.gov\/ct2\/show\/NCT04322565"},{"key":"10.1002\/14651858.CD015045-BIB0019|cit19","unstructured":"The ECLA PHRI COLCOVID trial. Effects of colchicine on moderate\/high-risk hospitalized COVID-19 patients (COLCOVID) clinicaltrials.gov\/show\/NCT04328480"},{"key":"10.1002\/14651858.CD015045-BIB0020|cit20","unstructured":"Trial to study the benefit of colchicine in patients with COVID-19 (COL-COVID) clinicaltrials.gov\/show\/NCT04350320"},{"key":"10.1002\/14651858.CD015045-BIB0021|cit21","unstructured":"Colchicine to reduce myocardial injury in COVID-19 (COLHEART-19) clinicaltrials.gov\/show\/NCT04355143"},{"key":"10.1002\/14651858.CD015045-BIB0022|cit22","unstructured":"Colchicine vs current standard of care in hospitalized patients with COVID-19 and cardiac injury clinicaltrials.gov\/show\/NCT04510038"},{"key":"10.1002\/14651858.CD015045-BIB0023|cit23","unstructured":"Colchicine in moderate symptomatic COVID-19 patients: double blind, randomized, placebo controlled trial to observe the efficacy clinicaltrials.gov\/show\/NCT04527562"},{"key":"10.1002\/14651858.CD015045-BIB0024|cit24","doi-asserted-by":"crossref","unstructured":"Efficacy of colchicine in moderately symptomatic COVID-19 patients: a study protocol for a double-blind, randomized, placebo-controlled trial 2021 8 1 www.ijclinicaltrials.com\/index.php\/ijct\/article\/view\/465","DOI":"10.18203\/2349-3259.ijct20210144"},{"key":"10.1002\/14651858.CD015045-BIB0025|cit25","unstructured":"Colchicine for the treatment of cardiac injury in hospitalized patients with COVID-19 (COLHEART-19) clinicaltrials.gov\/ct2\/show\/NCT04762771"},{"key":"10.1002\/14651858.CD015045-BIB0026|cit26","unstructured":"Salehdazeh F Pourfarzi F Ataei S The impact of colchicine on the COVID-19 patients; a clinical trial study www.researchsquare.com\/article\/rs-69374\/v1 10.21203\/rs.3.rs-69374\/v1"},{"key":"10.1002\/14651858.CD015045-BIB0027|cit27","unstructured":"Randomized open-blind controlled trial to study the benefit of colchicine in patients with COVID-19 www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2020-001511-25"},{"key":"10.1002\/14651858.CD015045-BIB0028|cit28","unstructured":"Colchicine for the treatment of hyperinflammation associated with pneumonia due to COVID-19 www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-001841-38\/ES"},{"key":"10.1002\/14651858.CD015045-BIB0029|cit29","unstructured":"A trial evaluating treatments for suspected coronavirus infection in people aged 50 years and above with pre-existing conditions and those aged 65 years and above www.isrctn.com\/ISRCTN86534580 doi.org\/10.1186\/ISRCTN86534580"},{"key":"10.1002\/14651858.CD015045-BIB0030|cit30","unstructured":"PRINCIPLE COVID-19 treatments trial widens to under 50s and adds colchicine www.principletrial.org\/news\/principle-covid-19-treatments-trial-widens-to-under-50s-adds-colchicine?ref=image"},{"key":"10.1002\/14651858.CD015045-BIB0031|cit31","unstructured":"A randomized double-blind placebo controlled phase 2 clinical trial to assess anti-inflammatory effect of colchicine (DRC3633) in mild to moderately severe COVID-19 patients (DRC-06C) jrct.niph.go.jp\/en-latest-detail\/jRCT2071200078"},{"key":"10.1002\/14651858.CD015045-BIB0032|cit32","unstructured":"Anti-coronavirus therapies to prevent progression of coronavirus disease 2019 (COVID-19) Trial (ACTCOVID19) clinicaltrials.gov\/ct2\/show\/NCT04324463"},{"issue":"1","key":"10.1002\/14651858.CD015045-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1186\/s13063-020-04455-3","article-title":"Adding colchicine to the antiretroviral medication \u2013 lopinavir\/ritonavir (Kaletra) in hospitalized patients with non-severe Covid-19 pneumonia: a structured summary of a study protocol for a randomized controlled trial","volume":"21","author":"Dalili","year":"2020","journal-title":"Trials"},{"key":"10.1002\/14651858.CD015045-BIB0034|cit34","unstructured":"The effects of standard protocol with or without colchicine in Covid-19 infection clinicaltrials.gov\/show\/NCT04360980"},{"key":"10.1002\/14651858.CD015045-BIB0035|cit35","unstructured":"Colchicine in moderate-severe hospitalized patients before ARDS to treat COVID-19 (COMBATCOVID19) clinicaltrials.gov\/show\/NCT04363437"},{"key":"10.1002\/14651858.CD015045-BIB0036|cit36","unstructured":"Colchicine twice daily during 10 days as an option for the treatment of symptoms induced by inflammation in patients with mild and severe coronavirus disease (ColchiVID) clinicaltrials.gov\/show\/NCT04367168"},{"key":"10.1002\/14651858.CD015045-BIB0037|cit37","unstructured":"Treatment with colchicine of patients affected by COVID-19: a pilot study www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-001475-33\/IT"},{"key":"10.1002\/14651858.CD015045-BIB0038|cit38","unstructured":"Colchicine in COVID-19: a pilot study (COLVID-19) clinicaltrials.gov\/show\/NCT04375202"},{"key":"10.1002\/14651858.CD015045-BIB0039|cit39","unstructured":"A randomization, multicentric, open-label, controlled, clinical trial to investigate the effectiveness of early colchicine administration in patients over 70 years of age with high risk of developing severe pulmonary complications associated with Coronavirus disease pneumonia (Covid-19) www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-001603-16\/ES"},{"key":"10.1002\/14651858.CD015045-BIB0040|cit40","unstructured":"Preemptive therapy with colchicine in patients older than 60 years with high risk of severe pneumoniae due to coronavirus (COLCHI-COVID) clinicaltrials.gov\/show\/NCT04416334"},{"key":"10.1002\/14651858.CD015045-BIB0041|cit41","unstructured":"Coronavirus edoxaban colchicine (CONVINCE) COVID-19 clinicaltrials.gov\/show\/NCT04516941"},{"key":"10.1002\/14651858.CD015045-BIB0042|cit42","unstructured":"Impact of colchicine in hospitalized Colombian patients with COVID-19 (COLCOVID19) clinicaltrials.gov\/show\/NCT04539873"},{"key":"10.1002\/14651858.CD015045-BIB0043|cit43","unstructured":"Study to investigate the treatment effect of colchicine in patients with COVID-19 clinicaltrials.gov\/show\/NCT04667780"},{"key":"10.1002\/14651858.CD015045-BIB0044|cit44","unstructured":"Survival trial using cytokines in COVID-19 (STRUCK) clinicaltrials.gov\/show\/NCT04724629"},{"key":"10.1002\/14651858.CD015045-BIB0045|cit45","unstructured":"Impact of colchicine and low-dose naltrexone on COVID-19 clinicaltrials.gov\/show\/NCT04756128"},{"key":"10.1002\/14651858.CD015045-BIB0046|cit46","unstructured":"Colchicine and post-COVID-19 pulmonary fibrosis clinicaltrials.gov\/ct2\/show\/NCT04818489"},{"key":"10.1002\/14651858.CD015045-BIB0047|cit47","unstructured":"Effectiveness of colchicine among patients with COVID-19 infection clinicaltrials.gov\/ct2\/show\/NCT04867226"},{"issue":"8","key":"10.1002\/14651858.CD015045-BIB0048|cit48","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010652.pub2","article-title":"Colchicine for pericarditis","author":"Alabed","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD015045-BIB0049|cit49","doi-asserted-by":"publisher","first-page":"659","DOI":"10.2174\/1381612824666180123110042","article-title":"Colchicine pharmacokinetics and mechanism of action","volume":"24","author":"Angelidis","year":"2018","journal-title":"Current Pharmaceutical Design"},{"issue":"9","key":"10.1002\/14651858.CD015045-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"e1003346","DOI":"10.1371\/journal.pmed.1003346","article-title":"Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: a living systematic review and meta-analysis","volume":"17","author":"Buitrago-Garcia","year":"2020","journal-title":"PLoS Medicine"},{"issue":"3","key":"10.1002\/14651858.CD015045-BIB0051|cit51","doi-asserted-by":"publisher","first-page":"e02325","DOI":"10.1128\/mBio.02325-17","article-title":"Role of severe acute respiratory syndrome coronavirus viroporins E, 3a, and 8a in replication and pathogenesis","volume":"9","author":"Casta\u00f1o-Rodriguez","year":"2018","journal-title":"mBio"},{"key":"10.1002\/14651858.CD015045-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"m1091","DOI":"10.1136\/bmj.m1091","article-title":"Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study","volume":"368","author":"Chen","year":"2020","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD015045-BIB0053|cit53","unstructured":"Guidance for the production and publication of Cochrane living systematic reviews: Cochrane Reviews in living mode community.cochrane.org\/review-production\/production-resources\/living-systematic-reviews"},{"key":"10.1002\/14651858.CD015045-BIB0054|cit54","unstructured":"Core outcome set developers\u2019 response to COVID-19 www.comet-initiative.org\/Studies\/Details\/1538"},{"issue":"2","key":"10.1002\/14651858.CD015045-BIB0055|cit55","doi-asserted-by":"publisher","first-page":"327","DOI":"10.23812\/CONTI-E","article-title":"Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies","volume":"34","author":"Conti","year":"2020","journal-title":"Journal of Biological Regulators and Homeostatic Agents"},{"key":"10.1002\/14651858.CD015045-BIB0056|cit56","unstructured":"Common terminology criteria for adverse events (CTCAE) ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm"},{"key":"10.1002\/14651858.CD015045-BIB0057|cit57","unstructured":"Deeks JJ Higgins JP Altman DG Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021 Available from training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015045-BIB0058|cit58","doi-asserted-by":"publisher","first-page":"108490","DOI":"10.1016\/j.clim.2020.108490","article-title":"Treating COVID-19 with colchicine in community healthcare setting","volume":"217","author":"Della-Torre","year":"2020","journal-title":"Clinical Immunology"},{"issue":"12","key":"10.1002\/14651858.CD015045-BIB0059|cit59","doi-asserted-by":"publisher","first-page":"e0242318","DOI":"10.1371\/journal.pone.0242318","article-title":"Colchicine reduces lung injury in experimental acute respiratory distress syndrome","volume":"15","author":"Dupuis","year":"2020","journal-title":"PloS One"},{"key":"10.1002\/14651858.CD015045-BIB0060|cit60","unstructured":"EndNote X9 Clarivate 2013"},{"issue":"5","key":"10.1002\/14651858.CD015045-BIB0061|cit61","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3109\/15563650.2010.495348","article-title":"Colchicine poisoning: the dark side of an ancient drug","volume":"48","author":"Finkelstein","year":"2010","journal-title":"Clinical Toxicology"},{"issue":"16","key":"10.1002\/14651858.CD015045-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"2100348","DOI":"10.2807\/1560-7917.ES.2021.26.16.2100348","article-title":"Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU\/EEA countries, weeks 38\/2020 to 10\/2021","volume":"26","author":"Funk","year":"2021","journal-title":"Eurosurveillance"},{"issue":"6","key":"10.1002\/14651858.CD015045-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/1440-1681.13488","article-title":"Colchicine treatment can improve outcomes of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis","volume":"48","author":"Hariyanto","year":"2021","journal-title":"Clinical and Experimental Pharmacology and Physiology"},{"key":"10.1002\/14651858.CD015045-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD015045-BIB0065|cit65","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021 Available from training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015045-BIB0066|cit66","unstructured":"Higgins JP Eldridge S Li T Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021 Available from training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015045-BIB0067|cit67","unstructured":"Higgins JP Lasserson T Chandler J Tovey D Thomas J Flemyng E Methodological expectations of Cochrane intervention reviews www.community.cochrane.org\/mecir-manual\/"},{"key":"10.1002\/14651858.CD015045-BIB0068|cit68","unstructured":"Higgins JP Savovic\u0301 J Page MJ Elbers RG Sterne JA Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021 Available from training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015045-BIB0069|cit69","unstructured":"Higgins JP Tianging L Deeks JJ Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021 Available from training.cochrane.org\/handbook"},{"issue":"10223","key":"10.1002\/14651858.CD015045-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"issue":"10","key":"10.1002\/14651858.CD015045-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"830","DOI":"10.2459\/JCM.0b013e3280110616","article-title":"CORP (COlchicine for Recurrent Pericarditis) and CORP-2 trials \u2013 two randomized placebo-controlled trials evaluating the clinical benefits of colchicine as adjunct to conventional therapy in the treatment and prevention of recurrent pericarditis: study design and rationale","volume":"8","author":"Imazio","year":"2007","journal-title":"Journal of Cardiovascular Medicine (Hagerstown)"},{"issue":"9","key":"10.1002\/14651858.CD015045-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S2213-2600(20)30316-7","article-title":"Case characteristics, resource use, and outcomes of 10\u2008021 patients with COVID-19 admitted to 920 German hospitals: an observational study","volume":"8","author":"Karagiannidis","year":"2020","journal-title":"Lancet Respiratory Medicine"},{"issue":"9","key":"10.1002\/14651858.CD015045-BIB0073|cit73","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013825.pub2","article-title":"SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19","author":"Kreuzberger","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD015045-BIB0074|cit74","doi-asserted-by":"publisher","first-page":"n526","DOI":"10.1136\/bmj.n526","article-title":"A living WHO guideline on drugs to prevent COVID-19","volume":"372","author":"Lamontagne","year":"2021","journal-title":"BMJ"},{"issue":"9","key":"10.1002\/14651858.CD015045-BIB0075|cit75","doi-asserted-by":"publisher","first-page":"577\u201382","DOI":"10.7326\/M20-0504","article-title":"The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application","volume":"172","author":"Lauer","year":"2020","journal-title":"Annals of Internal Medicine"},{"issue":"3","key":"10.1002\/14651858.CD015045-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.semarthrit.2015.06.013","article-title":"Colchicine \u2013 update on mechanisms of action and therapeutic uses","volume":"45","author":"Leung","year":"2015","journal-title":"Seminars in Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD015045-BIB0077|cit77","unstructured":"Li T Higgins JP Deeks JJ Chapter 5: Collecting data. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from training.cochrane.org\/handbook"},{"issue":"3","key":"10.1002\/14651858.CD015045-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S1470-2045(20)30096-6","article-title":"Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China","volume":"21","author":"Liang","year":"2020","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD015045-BIB0079|cit79","unstructured":"MAGICapp Norwegian MAGIC Evidence Ecosystem Foundation (powered by UserVoice Inc.) 2020"},{"key":"10.1002\/14651858.CD015045-BIB0080|cit80","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.atherosclerosis.2017.12.027","article-title":"The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation","volume":"269","author":"Mart\u00ednez","year":"2018","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1002\/14651858.CD015045-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.amjmed.2020.07.003","article-title":"Pathophysiological basis and rationale for early outpatient treatment of SARS-CoV-2 (COVID-19) infection","volume":"134","author":"McCullough","year":"2021","journal-title":"American Journal of Medicine"},{"key":"10.1002\/14651858.CD015045-BIB0082|cit82","unstructured":"Microsoft Excel Microsoft Corporation 2018"},{"issue":"5","key":"10.1002\/14651858.CD015045-BIB0083|cit83","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/ni.2550","article-title":"Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome","volume":"14","author":"Misawa","year":"2013","journal-title":"Nature Immunology"},{"issue":"10","key":"10.1002\/14651858.CD015045-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD015045-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"107723","DOI":"10.1016\/j.intimp.2021.107723","article-title":"Colchicine and mortality in patients with coronavirus disease 2019 (COVID-19) pneumonia: a systematic review, meta-analysis, and meta-regression","volume":"96","author":"Nawangsih","year":"2021","journal-title":"International Immunopharmacology"},{"key":"10.1002\/14651858.CD015045-BIB0086|cit86","unstructured":"National Institute for Health and Care Excellence COVID-19 rapid guideline: managing COVID-19, 2021 www.nice.org.uk\/guidance\/ng191"},{"key":"10.1002\/14651858.CD015045-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.virol.2015.08.010","article-title":"Severe acute respiratory syndrome coronavirus E protein transports calcium ions and activates the NLRP3 inflammasome","volume":"485","author":"Nieto-Torres","year":"2015","journal-title":"Virology"},{"issue":"3","key":"10.1002\/14651858.CD015045-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s11926-008-0036-3","article-title":"Colchicine: its mechanism of action and efficacy in crystal-induced inflammation","volume":"10","author":"Nuki","year":"2008","journal-title":"Current Rheumatology Reports"},{"issue":"5","key":"10.1002\/14651858.CD015045-BIB0089|cit89","doi-asserted-by":"publisher","first-page":"362","DOI":"10.7326\/M20-3012","article-title":"Prevalence of asymptomatic SARS-CoV-2 Infection: a narrative review","volume":"173","author":"Oran","year":"2020","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD015045-BIB0090|cit90","unstructured":"Page MJ Higgins JP Sterne JA Chapter 13: Assessing risk of bias due to missing results in a synthesis. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021 Available from www.training.cochrane.org\/handbook"},{"issue":"24","key":"10.1002\/14651858.CD015045-BIB0091|cit91","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"issue":"5","key":"10.1002\/14651858.CD015045-BIB0092|cit92","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013600.pub4","article-title":"Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review","author":"Piechotta","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD015045-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1186\/s13054-020-03022-1","article-title":"Acute complications and mortality in hospitalized patients with coronavirus disease 2019: a systematic review and meta-analysis","volume":"24","author":"Potere","year":"2020","journal-title":"Critical Care"},{"key":"10.1002\/14651858.CD015045-BIB0094|cit94","unstructured":"Review Manager Web (RevMan Web) The Cochrane Collaboration 2019"},{"key":"10.1002\/14651858.CD015045-BIB0095|cit95","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1136\/annrheumdis-2020-219174","article-title":"Anti-inflammatory therapy for COVID-19 infection: the case for colchicine","volume":"80","author":"Reyes","year":"2021","journal-title":"Annals of Rheumatic Diseases"},{"issue":"20","key":"10.1002\/14651858.CD015045-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1001\/jama.2020.6775","article-title":"Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area","volume":"323","author":"Richardson","year":"2020","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD015045-BIB0097|cit97","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jclinepi.2019.10.014","article-title":"GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions","volume":"119","author":"Santesso","year":"2020","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD015045-BIB0098|cit98","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015045-BIB0099|cit99","doi-asserted-by":"publisher","first-page":"m2980","DOI":"10.1136\/bmj.m2980","article-title":"Drug treatments for covid-19: living systematic review and network meta-analysis","volume":"370","author":"Siemieniuk","year":"2020","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD015045-BIB0100|cit100","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jclinepi.2017.08.008","article-title":"Living systematic reviews: 3. Statistical methods for updating meta-analyses","volume":"91","author":"Simmonds","year":"2017","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD015045-BIB0101|cit101","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.jclinepi.2019.10.015","article-title":"GRADE guidelines 27: how to calculate absolute effects for time-to-event outcomes in summary of findings tables and evidence profiles","volume":"118","author":"Skoetz","year":"2020","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD015045-BIB0102|cit102","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"7","key":"10.1002\/14651858.CD015045-BIB0103|cit103","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013665","article-title":"Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19 disease","author":"Struyf","year":"2020","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD015045-BIB0104|cit104","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"issue":"4","key":"10.1002\/14651858.CD015045-BIB0105|cit105","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrcardio.2017.161","article-title":"The NLRP3 inflammasome in acute myocardial infarction","volume":"15","author":"Toldo","year":"2018","journal-title":"Nature Reviews. Cardiology"},{"issue":"8","key":"10.1002\/14651858.CD015045-BIB0106|cit106","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006190.pub2","article-title":"Colchicine for acute gout","author":"Echteld","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD015045-BIB0107|cit107","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD014963","article-title":"Systemic corticosteroids for the treatment of COVID-19","author":"Wagner","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD015045-BIB0108|cit108","unstructured":"World Health Organization Cumulative number of reported probable cases of SARS www.who.int\/csr\/sars\/country\/2003_07_11\/en"},{"key":"10.1002\/14651858.CD015045-BIB0109|cit109","unstructured":"World Health Organization Middle East respiratory syndrome coronavirus (MERS-CoV) www.who.int\/emergencies\/mers-cov\/en"},{"key":"10.1002\/14651858.CD015045-BIB0110|cit110","unstructured":"World Health Organization Report of the WHO-China Joint Mission on coronavirus disease 2019 (COVID-19) www.who.int\/docs\/default-source\/coronaviruse\/who-china-joint-mission-on-covid-19-final-report"},{"key":"10.1002\/14651858.CD015045-BIB0111|cit111","unstructured":"WHO working group on the clinical characterisation and management of COVID-19 infection A minimal common outcome measure set for COVID-19 clinical research Lancet Infectious Diseases 2020 20 8 e192 7"},{"key":"10.1002\/14651858.CD015045-BIB0112|cit112","unstructured":"World Health Organization Corticosteroids for COVID-19 \u2013 living guidance 2 September 2020 www.who.int\/publications\/i\/item\/WHO-2019-nCoV-Corticosteroids-2020.1"},{"key":"10.1002\/14651858.CD015045-BIB0113|cit113","unstructured":"World Health Organization Draft landscape of COVID-19 candidate vaccines www.who.int\/publications\/m\/item\/draft-landscape-of-covid-19-candidate-vaccines"},{"key":"10.1002\/14651858.CD015045-BIB0114|cit114","unstructured":"World Health Organization WHO Coronavirus Disease (COVID-19) Dashboard covid19.who.int"},{"key":"10.1002\/14651858.CD015045-BIB0115|cit115","unstructured":"World Health Organization Coronavirus disease (COVID-19)\/COVID-19 vaccines\/Explainers www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/covid-19-vaccines\/explainers"},{"key":"10.1002\/14651858.CD015045-BIB0116|cit116","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","article-title":"Factors associated with COVID-19-related death using OpenSAFELY","volume":"584","author":"Williamson","year":"2020","journal-title":"Nature"},{"issue":"13","key":"10.1002\/14651858.CD015045-BIB0117|cit117","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1001\/jama.2020.2648","article-title":"Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention","volume":"323","author":"Wu","year":"2020","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD015045-BIB0118|cit118","doi-asserted-by":"crossref","unstructured":"Mikolajewska A Piechotta V Mueller A Skoetz N Colchicin for the treatment of COVID-19 (part of German Ecosystem CEO-Sys) PROSPERO 2021 CRD42021239107 Available from: www.crd.york.ac.uk\/prospero\/display_record.php?ID=CRD42021239107","DOI":"10.1002\/14651858.CD015045"},{"key":"10.1002\/14651858.CD015045-BIB0119|cit119","doi-asserted-by":"crossref","unstructured":"Mikolajewska A Piechotta V Mueller A Becker M Dorando E Risk of bias assessment for the Cochrane review \"Colchicine for the treatment of COVID-19\" zenodo.org\/record\/5377507 2021 10.5281\/zenodo.5377507","DOI":"10.1002\/14651858.CD015045"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,12,27]],"date-time":"2023-12-27T04:49:23Z","timestamp":1703652563000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD015045"}},"subtitle":[],"editor":[{"name":"Cochrane Haematology Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,10,18]]},"references-count":119,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,10]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd015045","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,18]]}}}